ConcertAI's Digital Trial Solution will be integrated into QCCA's network of 18 community-based oncology practices. This is the first time an oncology-specific digital clinical trials technology platform has been deployed on a national scale.
FREMONT, CA: Quality Cancer Care Alliance Network (QCCA), the first national clinically integrated network of community oncology practices, has chosen ConcertAI as its exclusive partner for digital clinical trials. ConcertAI is one of the market leaders for Real-World Evidence (RWE) and enterprise AI Software-as-a-Service (SaaS) technology solutions for precision oncology, hematology, and urology.
ConcertAI's Digital Trial Solution will be integrated into QCCA's network of 18 community-based oncology practices. This is the first time an oncology-specific digital clinical trials technology platform has been deployed on a national scale. The solution is unique in that it provides end-to-end clinical trial support and is integrated into practice care management processes, reducing the burden on healthcare providers and increasing access to critical clinical trials for patients who may have more limited and less viable standard-of-care options.
"In hard-to-treat cancers, clinical trials are increasingly a viable and important option for patients," stated Dr. Sibel Blau MD, CEO and President, QCCA. "Our partnership with ConcertAI will transform how we conduct clinical research and increase the number of high-value trials available in the community where patients live and have the greatest support."
